Alzheimer Cafè: toward bridging the gap between cure and care in patients with dementia
Alzheimer’s disease (AD) is the most common form of degenerative dementia, Bio Med Frontiers whose symptoms usually appear in the pre-senile age. In the early stages, patients present social difficulties due to the general cognitive decline in memory, language and executive domains.
These problems also affect patients quality of life, emotions, and mood, leading to social isolation. The aim of this study is to evaluate the effects of Alzheimer’s Cafè (AC) on the cognitive and behavioral outcomes of AD patients.
Twenty patients diagnosed with AD, who attended the Cognitive and Behavioral Rehabilitation Laboratory of the IRCCS Centro Neurolesi “Bonino-Pulejo” of Messina, Italy, from December 2017 to December 2018, were enrolled in this study. As these patients belonged to the experimental group (EG: n = 20), they received specific cognitive-behavior training using the AC modality.
The patients were assessed by a neuropsychological evaluation at the beginning and at the end of the program.
Their outcomes were compared to a matched group of patients with neurodegenerative dementia (CG: 20) receiving conventional cognitive training. The pre-post comparisons showed that both CG and EG had a significant improvement in global cognitive functioning (MoCA p < 0.001) and in perceived quality of life (<0.001).
However, only in the EG, we observed a significant increase in social functioning (SASS p < 0.00), the perception of mental well-being (SF-12 Mental p < 0.00), and a reduction in the depressive state (GDS p < 0.00).
The present study suggests the importance of AC for patients with AD and the potential effect on psychological and social well-being.
Light microscopy and scanning electron microscopy: A helping tool to identify the adultrant of dye from Curcuma longa L rhizome, and its ecofriendly applications on pharmaceutical products.
- The current study was embraced to examine the morphoanatomical distinguishing proof utilizing light microscopy (LM), scanning electron microscopy (SEM), and Study More antibacterial activities of turmeric extract utilizing amoxicillin and ciprofloxacin.
- Cross over part of the rhizome is roundabout in structure. The peripheral layer is the periderm which comprises of 6-7 layers of digressively lengthened cells. This is trailed by an expansive cortex made of flimsy walled parenchyma cells with intercellular spaces.
- The antibacterial activities of turmeric extract in blend with drug items like amoxicillin and ciprofloxacin were likewise examined at various fixations.
- Different turmeric samples and drug items were gathered from various shops of Lahore. The samples were analyzed for antibacterial activities by utilizing pour plate method.
- In general outcomes showed a fundamentally higher zone of inhibition of turmeric extract in combination with ciprofloxacin and a lower zone of inhibition of turmeric extract in combination with amoxicillin. It is inferred that turmeric extract have hostile impact in blend with amoxicillin.
- Thus, the combination of turmeric extract with antimicrobial (amoxicillin) diminished the intensity of antibiotic. The turmeric extract have more antibacterial activity in mix with ciprofloxacin. Thus, the blend of turmeric extract with antibiotic (ciprofloxacin) expanded the intensity of antibiotic.
Identification and triage of a Morel-Lavallée lesion using point of care ultrasound.
A Morel-Lavallée lesion is a relatively rare, closed, degloving injury. Polytrauma and severe injuries through to seemingly innocuous trauma can distract the clinician from thorough assessment of the affected site. Missed or misdiagnosis of the closed lesion is reported from both a clinical and imaging perspective.
- A 46-year-old male is discharged from accident and emergency with a shoulder injury following a cycling accident. Ten days post trauma, an advanced practice physiotherapist suspects a lateral thigh Morel-Lavallée lesion during a telephone assessment (Covid-19 restrictions). A face to face appointment with imaging the following day confirmed the suspicion.
- The aetiology, imaging and clinical management of a Morel-Lavallée lesion is discussed. The addition of diagnostic ultrasound skills to clinical assessment in this case report may have improved patient care and experience by offering a ‘one-stop shop‘ to care. Formal training in musculoskeletal ultrasound imaging is emphasised.
- Thorough history taking, clinical reasoning and subsequent application of robust imaging led to the identification of a Morel-Lavellée lesion and, in this case, highlights the value of a point of care ultrasound model in a triage setting.
- The prevalence of binge eating disorder and associated psychiatric and substance use disorders in a student population in Kenya – towards a public health approach.
Kenya in particular and Africa in general lack data on Binge Eating Disorder (BED). The overarching objective of this study is to fill that gap.
Kenyans may not be aware that BED exists when a “very good” appetite is considered a sign of good health, especially if food is available either at home, in fast food shops or when communally eating together a very common cultural practice. On the other hand, where there is relatively insufficient food, it is not expected that one could be having a problem of eating too much.
We administered the following tools and measurements to 9742 participants (high school, college, and university students):
1) Researcher designed socio-demographic and economic indicator questionnaire;
2) An instrument documenting DSM-IV diagnostic criteria for BED and its various symptoms;
3) An instrument to determine DSM-IV psychiatric disorders and substance abuse;
4) An instrument measuring high risk for psychosis ,affectivity and stress;
5) A WHO-designed instrument measuring the severity of substance abuse for specific substances.
We used descriptive and inferential analysis to determine the prevalence and association of the different variables.
Independent predictors of BED were generated from a generalized linear model (p<0.05).
We found a prevalence of 3.2% of BED and a wide range of prevalence for BED and BED related symptoms (8.1% to 19%). The least prevalent was “To prevent weight gain from eating binge did you force yourself to vomit, or used laxatives?”.
The most common was “Did you often go on eating binges (eating a very large amount of food very quickly over a short period of time).”
Major depression, obsessive-compulsive disorder, panic disorder, agoraphobia, generalized anxiety disorder ,a positive stress screen and drug abuse were independent predictors of BED (p<0.05).
Our findings on the prevalence of BED and significant associations with various psychiatric disorders and substance use disorders are similar to those obtained in High-Income Countries (HIC) using similar large-scale samples in non-clinical populations.
Our findings suggest the need fora public health approach to enhance awareness of BED and to promote health-seeking behaviour towards management of BED.
Keywords: Binge Eating; Co-morbidity; Eating Disorders; Kenya.
One-year outcomes of CCTA alone versus machine learning-based FFR CT for coronary artery disease: a single-center, prospective study.
To explore downstream management and outcomes of machine learning (ML)-based CT derived fractional flow reserve (FFRCT) strategy compared with an anatomical coronary computed tomography angiography (CCTA) alone assessment in participants with intermediate coronary artery stenosis.
In this prospective study conducted from April 2018 to March 2019, participants were assigned to either the CCTA or FFRCT group.
The primary endpoint was the rate of invasive coronary angiography (ICA) that demonstrated non-obstructive disease at 90 days.
Secondary endpoints included coronary revascularization and major adverse cardiovascular events (MACE) at 1-year follow-up.
In total, 567 participants were allocated to the CCTA group and 566 to the FFRCT group. At 90 days, the rate of ICA without obstructive disease was higher in the CCTA group (33.3%, 39/117) than that (19.8%, 19/96) in the FFRCT group (risk difference [RD] = 13.5%, 95% confidence interval [CI]: 8.4%, 18.6%; p = 0.03).
The ICA referral rate was higher in the CCTA group (27.5%, 156/567) than in the FFRCT group (20.3%, 115/566) (RD = 7.2%, 95% CI: 2.3%, 12.1%; p = 0.003). The revascularization-to-ICA ratio was lower in the CCTA group than that in the FFRCT group (RD = 19.8%, 95% CI: 14.1%, 25.5%, p = 0.002).
MACE was more common in the CCTA group than that in the FFRCT group at 1 year (HR: 1.73; 95% CI: 1.01, 2.95; p = 0.04).
In patients with intermediate stenosis, the FFRCT strategy appears to be associated with a lower rate of referral for ICA, ICA without obstructive disease, and 1-year MACE when compared to the anatomical CCTA alone strategy.
2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) |
|||
| GEN-402-25tests | All test | 25 tests | 292.8 EUR |
shop Antibody |
|||
| CSB-PA893341XA01DLU-02mg | Cusabio | 0.2mg | Ask for price |
shop Antibody |
|||
| CSB-PA893341XA01DLU-10mg | Cusabio | 10mg | Ask for price |
shop Antibody |
|||
| MBS9014248-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Shoc2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6658105 | ABM | 3 x 1.0 ug | 451.2 EUR |
Shox2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6866205 | ABM | 3 x 1.0 ug | 451.2 EUR |
SHOX sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2145505 | ABM | 3 x 1.0 ug | 451.2 EUR |
ALL-PO |
|||
| ABC-TC449S | AcceGen | 1 vial | Ask for price |
SHOC2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2145405 | ABM | 3 x 1.0 ug | 451.2 EUR |
SHOX2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2145605 | ABM | 3 x 1.0 ug | 451.2 EUR |
Shox2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3906705 | ABM | 3 x 1.0 ug | 451.2 EUR |
Shoc2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K4802705 | ABM | 3 x 1.0 ug | 451.2 EUR |
Shoc2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6658106 | ABM | 1.0 ug DNA | 200.4 EUR |
Shoc2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6658107 | ABM | 1.0 ug DNA | 200.4 EUR |
Shoc2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6658108 | ABM | 1.0 ug DNA | 200.4 EUR |
Shox2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6866206 | ABM | 1.0 ug DNA | 200.4 EUR |
Shox2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6866207 | ABM | 1.0 ug DNA | 200.4 EUR |
Shox2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6866208 | ABM | 1.0 ug DNA | 200.4 EUR |
In stable patients with intermediate stenosis, ML-based FFRCT strategy was associated with a lower referral ICA rate, a lower normalcy rate of ICA, and a higher revascularization-to-ICA ratio than the CCTA strategy. •
Compared with the CCTA strategy, ML-based FFRCTshows superior outcome prediction value which appears to be associated with a lower rate of 1-year MACE. • ML-based FFRCT strategy as a non-invasive “one-stop-shop” modality may be the potential to change diagnostic workflows in patients with suspected coronary artery disease.
